Different diagnostic and prognostic groups of colorectal carcinoma (CRC) have been defined. However, accurate diagnosis and prediction of survival are sometimes difficult. Gene expression profiling might improve these classifications and bring new insights into underlying molecular mechanisms. We profiled 50 cancerous and noncancerous colon tissues using DNA microarrrays consisting of B8000 spotted human cDNA. Global hierarchical clustering was to some extent able to distinguish clinically relevant subgroups, normal versus cancer tissues and metastatic versus nonmetastatic tumours. Supervised analyses improved these segregations by identifying sets of genes that discriminated between normal and tumour tissues, tumours associated or not with lymph node invasion or genetic instability, and tumours from the right or left colon. A similar approach identified a gene set that divided patients with significantly different 5-year survival (100% in one group and 40% in the other group; P ¼ 0.005). Discriminator genes were associated with various cellular processes. An immunohistochemical study on 382 tumour and normal samples deposited onto a tissue microarray subsequently validated the upregulation of NM23 in CRC and a downregulation in poor prognosis tumours. These results suggest that microarrays may provide means to improve the classification of CRC, provide new potential targets against carcinogenesis and new diagnostic and/or prognostic markers and therapeutic targets.
Introduction
Despite progresses made during the last decades, colorectal cancer (CRC) remains one of the most frequent and deadly neoplasias in the Western countries. Current prognostic models based on histoclinical parameters apprehend only poorly the heterogeneity of disease and are not accurate enough for prediction in the individual patient. Tumours with different genetic alterations, developing in different host backgrounds, may have the same clinical presentation but follow quite different evolutions. One goal of molecular analysis is to identify, among complex networks of molecules involved in progression, markers that could differentiate subgroups of tumours with distinct behaviour and prognosis allowing patients to receive appropriate treatment.
Molecular studies have been largely focused on individual candidate genes, contrasting with the molecular complexity of disease. The multistep progression of CRC requires years and possibly decades and is accompanied by a number of genetic alterations (KRAS, APC, P53 and mismatch repair (MMR) genes, WNT and TGFb pathways) that accumulate and combine their effects (Vogelstein et al., 1988; Fearon and Vogelstein, 1990) . Despite the huge amount of studies, applications remain limited for CRC patients. Little is known about molecular alterations associated with the heterogeneity of disease, and no molecular marker has been validated for use as a new diagnostic or prognostic parameter applicable to routine clinical practice. New models based on a deeper molecular understanding of disease are required to improve screening, diagnosis, treatment and ultimately survival.
DNA microarray technology allows the measure of the mRNA expression level of thousands of genes simultaneously in a single assay, thus providing a molecular definition of a sample adapted to tackle the combinatory and complex nature of cancers (Bertucci et al., 2001; Mohr et al., 2002) . Gene expression profiling can reveal biologically and/or clinically relevant subgroups of tumours (Alizadeh et al., 2000; Garber et al., 2001; Beer et al., 2002; Bertucci et al., 2002; Devilard et al., 2002; Singh et al., 2002) and improve our mechanistic understanding of oncogenesis.
Gene expression profiling-based studies of CRC have so far compared normal and tumour tissue samples or different stages of disease (Alon et al., 1999; Backert et al., 1999; Hegde et al., 2001; Kitahara et al., 2001; Notterman et al., 2001; Agrawal et al., 2002; Birkenkamp-Demtroder et al., 2002; Lin et al., 2002; Zou et al., 2002; Frederiksen et al., 2003; Tureci et al., 2003; Williams et al., 2003) , but none has directly addressed the issue of prognosis or MSI phenotype. Here we have applied DNA microarray technology to analyse the expression of B8000 genes in 50 cancer and noncancerous colon tissue samples. Unsupervised hierarchical clustering discovered new subgroups of tumours. Supervised analysis identified several genes differentially expressed between normal and cancer samples and between subgroups of colon cancer defined upon histoclinical parameters, including clinical outcome and MSI phenotype. Some of the potential markers were further studied using immunohistochemistry (IHC) on sections of tissue microarrays (TMA).
Results

Gene expression profiling of CRC and unsupervised classification
The mRNA expression profiles of 50 cancer and noncancerous colon samples (45 clinical tissue samples and five cell lines) (Table 1) were determined using DNA microarrays containing B8000 spotted PCR products from known genes and expressed sequence tags (ESTs). Analyses of normalized expression levels were both unsupervised and supervised.
Unsupervised hierarchical clustering of all samples was first applied, based on the expression profile of genes with a significant variation in expression level across all the experiments. Results are displayed in a colour-coded matrix ( Figure 1a ) where samples are ordered on the horizontal axis and genes on the vertical axis on the basis of similarity of their expression profiles. The 50 samples were sorted into two large clusters that extensively differed with respect to normal or cancer type (Figure 1b, top) : 87% were noncancerous in the left cluster and 87% were cancerous in the right cluster. As expected, the CRC cell lines represented a branch of the 'cancer' cluster. Hierarchical clustering also allowed identification of gene clusters corresponding to defined functions or cell types, several of which are indicated by coloured bars on the right of Figure 1a and are zoomed in Figure 1b . Three are overexpressed in tissue samples overall as compared to epithelial cell lines, reflecting the cell heterogeneity of tissues: an 'immune cluster' with different subclusters including an MHC class I subcluster that correlated with an interferon-related subcluster, and an MHC class II subcluster, a 'stromal cluster' rich in genes expressed in stromal cells (COL1A1, COL1A2, COL3A1, MMP2, TIMP1,  SPARC, CSPG2, PECAM, INHBA) , and a 'smooth muscle cluster' (CNN1, CALD1, DES, MYH11, SMTN, TAGL) that was globally overexpressed in normal tissues as compared to cancer tissues. An 'early-response cluster' included immediate-early genes (JUNB, FOS, EGR1, NR4A1, DUSP1) involved in the human cellular G  pT3  pN1  2  MSI  cS+adj CT  NED 56  8904  M  80  Descending colon  G  pT3  pN1  2  MSI  cS  NED 18  6974  M  68  Ascending colon  P  pT3  pN1  2  MSI  cS+adj CT  NED 97  8646  M  74  Descending colon  G  pT3  pN1  2  MSS  cS  NED 63  8458  M  56  Descending colon  G  pT3  pN1  2  MSS  cS+adj CT  NED 69  6992  F  65  Ascending colon  G  pT3  pN1  2  MSS  cS+adj CT  NED 98  7094  F  87  Descending colon  G  pT3  pN1  2  MSS  cS  NED 64  8252  F  54  Rectum  G  pT4  pN1  2  MSS  cS+adj CT  NED 74  9075  F  45  Ascending colon  G  pT2  pN1  1  MSI  cS  MR 23 -D 38  7505  M  71  Ascending colon  G  pT1  pN1  1  MSI  cS  NED 88  7043  M  70  Descending colon  G  pT2  pN1  1  MSS  cS  NED 97  6952  M  58  Descending colon  G  pT2  pN1  1  MSS  cS  NED 65  7597  F  72  Rectum  G  pT2  pN1  1  MSS  cS  NED 87  7815  M  63  Rectum  G  pT2  pN1  1  MSI  cS  MR 10 -D Figure 1a ), so-called 'proliferation cluster', was generally overexpressed in cell lines as compared to tissues, probably reflecting the proliferation rate difference between cells in culture and tumour tissues. It included PCNA that codes for a proliferation marker used in clinical practice as well as many genes involved in glycolysis (such as GAPD, LDHA, ENO1), in cell cycle and mitosis (such as CDK4, BUB3, TUBB), in metabolism (such as ALDH3A1), cytochrome c oxidase subunits, GSTP1, and in protein synthesis such as genes coding for ribosomal proteins (data not shown). Remarkably, the same clustering algorithm applied only to the 22 CRC clinical samples sorted two groups of tumours (A, 12 patients and B, 10 patients) that differed with respect to AJCC stage and clinical outcome (Figure 1c) . Group A included a high proportion of patients presenting with metastases at diagnosis (AJCC4 stage, six out of 12) as compared with group B (0 out of 10). Interestingly, three out of six 'AJCC1-3 patients' of group A experienced metastatic relapse after a median duration of 18 months (range 4-88) from diagnosis and died from CRC, while none out of 10 'AJCC1-3 patients' of group B relapsed nor died after a median follow-up of 69 months (range 10-98). This suggests that tumours are at higher risk of metastasis in group A than in group B. To identify particular sets of genes that could better define subgroups of samples, we next focused on supervised analyses.
Differential gene expression between normal colon and colon tumours
To identify and rank genes with significant differential expression between cancer (22 samples) and noncancerous tissues (23 samples), we applied discriminating score (DS) combined with iterative random permutation tests. We identified 245 cDNA clones (see Supplemental (Figure 2 ) with a 
Differential gene expression within CRC tissue samples
A supervised approach was applied to the 22 cancer tissue samples by comparing tumour subgroups defined upon relevant histoclinical parameters.
Genes associated with visceral metastases
Presence or occurrence of metastasis is the leading cause of death in CRC. Accurate predictors of metastasis are needed to tailor therapeutic strategies and improve survival. We identified 244 cDNA clones (see Supplemental Table 2 ), corresponding to 235 unique sequences representing 194 characterized genes and 41 ESTs, which best discriminated between samples associated with and without metastasis at diagnosis or during follow-up. Among these clones, 219 were downregulated and 25 were upregulated in metastatic samples as compared to nonmetastatic samples. Hierarchical clustering of samples based on the expression of these selected genes (Figure 3a and b) successfully classified them according to outcome, with only two nonmetastatic samples misplaced in group 2. Differences of survival between the two groups were statistically significant ( Figure 3c ). With a median follow-up of 66 months (range 4-98), the 5-year metastasis-free survival (MFS) and overall survival (OS) were 100% for group 1 (n ¼ 11) and respectively 18 and 30% for group 2 (n ¼ 11) (P ¼ 0.0001 and 0.001). When only considering patients without metastatic disease at the time of diagnosis (AJCC1-3 stage), the 5-year MFS and OS were 100% for group 1 (n ¼ 11) and 40% for group 2 (n ¼ 5) (P ¼ 0.005 and 0.006, respectively). Finally, when only 'AJCC1-2 patients' (no metastatic disease and node-negative tumour at the time of diagnosis) were considered, they were 100% for group 1 (n ¼ 10) and 50% for group 2 (n ¼ 4) (P ¼ 0.019 and 0.022, respectively).
To estimate the accuracy of prediction of our molecular signature and the validity of our procedure, we used a 'leave-one-out' crossvalidation testing method (Golub et al., 1999) . Iteratively, one of the 22 cancer samples was removed from the group, and a new set of discriminator genes was generated from the remaining 21 samples. The test sample was then classified with the other samples by using the predictive gene set and according to the difference of the correlation coefficients between its expression profile and the median profile of nonmetastatic samples and between its expression profile and the median profile of metastatic samples. It was classified as low or high risk of metastasis, depending on whether that difference was positive or negative, respectively. This process was repeated for each of the 22 samples. The prediction was considered correct if it corresponded to the actual outcome. Out of 22 samples, 18 (82%) were correctly assigned by the predictors (data not shown), with an accuracy rate of 89% for samples with metastasis and 77% for nonmetastatic samples. In fact, two misclassified samples (8904T and 7650T) displayed intermediate correlations, in agreement with their intermediate expression profile shown in Figure 3 , and probably represent a different class of samples. Although the predictive gene set generated by each of the crossvalidation loops was slightly different at each iteration, on average 80% of the genes of our signature were conserved.
Genes associated with lymph node metastases
Pathological lymph node involvement at diagnosis is a strong prognostic parameter in CRC. Its determination relies on surgical dissection. But lymph node invasion is imprecise for determining clinical outcome. Node status reflects the tumour expression of many genes, and subtle molecular alterations important for clinical outcome may be hidden. Large-scale expression analyses provide an opportunity to identify those genes. We identified 46 cDNA clones (41 known genes and five ESTs) as significantly differentially expressed between tumours with (n ¼ 5) and without (n ¼ 16) lymph node metastases. Reclustering based on these 46 genes correctly separated node-positive from node-negative samples ( Figure 4a ). The two samples (9075T and 7442T) that, among all node-negative cases, had expression patterns 
Genes associated with MSI phenotype and with location of cancer
To obtain additional insights into colorectal oncogenesis, we next analysed differential gene expression between MSI þ (n ¼ 8) and non-MSI (n ¼ 14) tumours and between tumours from right colon (n ¼ 6) and left colon (n ¼ 13).
We identified 58 cDNA clones (representing 51 known genes and five ESTs) with significant differential expression between MSI þ and non-MSI tumours. Their discriminator potential was confirmed by the rather successful hierarchical classification of samples based on their expression levels, even if some MSI þ tumours displayed an intermediate expression profile (Figure 4b) . Similarly, classification of 19 samples (excluding transverse colon tumours), based on the expression of 46 cDNA genes (35 known genes and 11 ESTs) differentially expressed between right and left colon cancers, correctly sorted samples from the right or left colon (Figure 4c ). Such discrimination agreed with the existence of two distinct categories of CRC according to the location of tumour (Iacopetta, 2002) .
Immunohistochemistry on tissue microarrays
We sought to measure the IHC expression levels of five proteins coded by discriminator genes identified in our supervised analyses. These genes were selected because of a putative role in colorectal oncogenesis or metastatic process and the commercial availability of a corresponding monoclonal antibody: RACK1, NTRK2, NM23, Decorin and Prohibitin. We constructed a TMA containing 191 pairs of cancer samples and the corresponding normal mucosa (Table 2) . Two antibodies -anti-RACK1 and anti-NTRK2 -did not perform sufficiently well in IHC on paraffin-embedded tissues. Moreover, as previously described (Ginestier et al., 2002) , correlation between protein and mRNA levels was not found for Decorin and Prohibitin. The results were satisfactory for anti-NM23 antibody, which As found with DNA microarrays, NM23 was significantly overexpressed in cancer samples as compared to noncancerous samples (P ¼ 5.6 Â 10 À6 , Fisher's exact test). In univariate analysis, it was significantly downregulated in tumours with metastasis (cutoff was the median value) compared to tumours without metastasis (P ¼ 0.04, Fisher's exact test). The 5-year MFS was 68% for negative and 88% for positive samples when considering the 'AJCC1-3 patients' (P ¼ 0.03, log-rank test). The 5-year OS was 42% for negative and 63% for positive samples when considering all the patients (P ¼ 0.03, log-rank test). Multivariate analysis was then conducted to assess the significance of these associations when we took into account the other classical prognostic factors (AJCC stage, grade of differentiation, vascular invasion, age of patients). Patients with positive NM23 status displayed a lower risk of metastasis (adjusted odds ratio 0.37, 95% CI 0.13-1.12) and death from CRC (adjusted odds ratio 0.66, 95% CI 0.40-1.10) than patients with negative NM23 status, but the differences were not significant (P ¼ 0.07 and 0.12, respectively).
Discussion
DNA microarray-based gene expression profiling is a promising approach to investigate the molecular complexity of cancer. To date, CRC studies (Alon et al., 1999; Backert et al., 1999; Hegde et al., 2001; Kitahara et al., 2001; Notterman et al., 2001; Agrawal et al., 2002; Birkenkamp-Demtroder et al., 2002; Lin et al., 2002; Zou et al., 2002; Frederiksen et al., 2003; Tureci et al., 2003; Williams et al., 2003) have not directly addressed the issue of prognosis or MSI phenotype. Here, we profiled 50 cancer and noncancerous colon tissue samples and correlated expression profiles with histoclinical parameters of disease, including survival.
Unsupervised analysis
The global gene expression profile revealed extensive transcriptional heterogeneity between samples, notably cancer samples. It was to some extent already able to distinguish clinically relevant subgroups of samples: normal versus cancer tissues as previously reported (Bhattacharjee et al., 2001; Welsh et al., 2001a; Hippo et al., 2002; Matei et al., 2002;  -Donahue et al., 2003) , notably for CRC (Alon et al., 1999; Notterman et al., 2001; Lin et al., 2002) , and good versus poor prognosis tumours (Bertucci et al., 2000; Takahashi et al., 2001; van 't Veer et al., 2002) . Such global classification is usually imperfect because of the excessive noise generated by a large gene set that masks the distinction of interest (such as clinical outcome) governed by a smaller set. Nevertheless, a preliminary global approach allows identification of broad coherent expression patterns within the mass of data: for example, we identified several gene clusters that corresponded to cell types (stroma, smooth muscle, MHC class I and II) or functions (interferon-related, immediate-early response and proliferation), which have been already reported in previous studies (Shaffer et al., 2001; Welsh et al., 2001b; Bertucci et al., 2002) .
Supervised analyses
To identify smaller sets of discriminator genes that can improve classification of samples and facilitate translation in clinical practice, supervised analyses were carried out, based on predefined groups of samples.
Comparison of normal versus cancer samples
A total of 245 discriminator cDNA clones (3%) were significantly differentially expressed between normal and cancer samples. This ratio is in agreement with other reports (Zhang et al., 1997; Stremmel et al., 2002) . Comparison with lists of discriminator genes previously identified in CRC using DNA microarrays (Alon et al., 1999; Backert et al., 1999; Kitahara et al., 2001; Notterman et al., 2001; Agrawal et al., 2002; Birkenkamp-Demtroder et al., 2002; Lin et al., 2002; Zou et al., 2002; Frederiksen et al., 2003; Tureci et al., 2003; Williams et al., 2003) revealed many common genes, further emphasizing the validity of our data. For example, CA4, CHGA, CNN1, MYH11, FCGBP, KCNMB1 and SST were downregulated, whereas CA3, CCT4, EIF3S6 or EEF1A1, IFITM1, CSE1L, NME1 or RAN were upregulated in cancer samples. In addition to these genes, we identified many other genes.
Among the downregulated genes in cancer samples were genes encoding cytokines (IL10RA, IL1RN, IL2RB) , proteins involved in lipid metabolism (LPP, LIAS, LRP2, MGLL) (BirkenkampDemtroder et al., 2002) , signal transducers (PLCD1, PLCG2, mTOR/FRAP1) , transcription factors such as RELA, and other known or putative tumour suppressor genes (TSG) such as CTCF that encodes a transcriptional repressor of MYC and is located in 16q22.1, chromosomal region frequently deleted in human tumours (Filippova et al., 1998) and IRF1, a transcriptional activator of genes induced by cytokines and growth factors, which regulates apoptosis and cell proliferation and is frequently deficient in human cancers (Tamura et al., 1996) . The downregulation of GSN (gelsolin), combined with that of PRKCB1, may concur to decrease the activation of PKCs involved in phospholipid signalling pathways and inhibit cell proliferation and tumorigenicity (Sagawa et al., 2003) .
The top-ranked gene overexpressed in cancer samples was GNB2L1 (also named RACK1) that encodes a homologue of the beta subunit of G proteins involved in signal transduction and activation of PKC. GNB2L1 interacts with IGF1R, an important player in colorectal oncogenesis (Furstenberger and Senn, 2002) . This interaction can regulate IGF1-mediated AKT activation and protection from cell death (Kiely et al., 2002) as well as IGF1-dependent integrin signalling and promote cell spreading and contact with the extracellular matrix (ECM) (Hermanto et al., 2002) .
Upregulated genes already reported for other types of cancer included the SNRPs and SOX transcription factors (SNRPC, SNRPE, SOX4, SOX9), components of ECM or molecules involved in its remodelling (COL5A1, P4HA1, MMP13, LAMR1) (Notterman et al., 2001; Agrawal et al., 2002; Hippo et al., 2002; Frederiksen et al., 2003; Williams et al., 2003) . We also identified BZRP that codes for the peripheral benzodiazepine receptor (Maaser et al., 2002) , the cell cycle genes (CCNB2, CDK2), and SAT, involved in polyamine metabolism (Bettuzzi et al., 2000) . Unexpectedly, but as previously reported (Zhang et al., 1997; Tureci et al., 2003) , we found overexpression in cancer samples of SERPINB5 and NME1, encoding two potential TSGs. Upregulation of NME1 combined with underexpression of CTCF might concur to upregulate the MYC oncogene, a relevant target of the WNT/APC pathway in the development of CRC (Barker et al., 2000) . Other upregulated genes, and potential therapeutic targets, included kinases (PTK2, STK6, NTRK2), the cell-surface protein CD9, a member of the tetraspanin family (Iacobuzio-Donahue et al., 2003) and three genes encoding integrins ITGA2, ITGAL and ITGB3. The integrin pathway was further affected with variations in the expression of genes encoding PTK2, TGFB1I1/ HIC5 (a PTK2 interactor) and integrin-linked kinase ILK. Agrawal et al. (2002) previously identified osteopontin, an integrin-binding protein, as a marker of CRC progression. In our analysis, SPP1, which codes for osteopontin, as well as CXCL1, which codes for GRO1 oncogene (Notterman et al., 2001; Agrawal et al., 2002; Zou et al., 2002) or CDK4 (Wang et al., 1998), were not in our stringent list of discriminator genes, although overexpressed in cancer samples with a foldchange superior or equal to two.
Discriminator genes were associated with many cellular structures, processes and functions, including general metabolism (the most abundant category), cell cycle, proliferation, apoptosis, adhesion, cytoskeleton, signal transduction, transcription, translation, RNA and protein processing, immune system and others. Up-and downregulated genes were rather equally distributed with respect to these functions, except for those coding for kinases and for proteins involved in ECM remodelling, metabolism, RNA and protein processing (translation, ribosomal proteins and chaperonins), which were overexpressed in cancer samples. This phenomenon, already reported (Alon et al., 1999; Kitahara et al., 2001; Birkenkamp-Demtroder et al., 2002; Lin et al., 2002) , is likely to be related to increased metabolism and cell proliferation in cancer cells.
Analysis of chromosomal location pointed to two interesting regions. Six genes upregulated in tumours (STK6, UBE2C, PFDN4, RPS21, CSE1L, SLPI) were located in 20q13, a chromosomal region often amplified in cancer; their overexpression might be a consequence of gene amplification. This has already been observed by others (Ried et al., 1996; Korn et al., 1999; BirkenkampDemtroder et al., 2002; Platzer et al., 2002) although not all genes of the region are affected transcriptionally (Platzer et al., 2002) . Conversely, six genes (TJP3, INSR, ELAVL1, MAP2K7, CNN1, NR2F6) downregulated in cancer samples were located in 19p13.1-p13.3, already known to harbour several potential TSG such as APC2 (Nakagawa et al., 1998) , STK11 (Resta et al., 1998) or MCC2 (Ishikawa et al., 2001) .
Expression profiles and clinical outcome
All patients, some of them presenting with metastasis at diagnosis, had received standard treatment. It was noticeable that, according to global hierarchical clustering, most nonmetastatic tumours that clustered with metastatic cases eventually developed metastasis and died during follow-up. Supervised analysis further improved the classification by identifying 194 known genes and 41 ESTs that well discriminated between samples without or with metastasis at diagnosis or during follow-up. To our knowledge, this is the first report that suggests a potential prognostic role of gene expression profiling in CRC. We compared the significance of the prognostic classification made by AJCC stage and by our discriminator gene set. Classification based on AJCC stage ('AJCC1-2 tumours', n ¼ 14, versus 'AJCC3-4 tumours', n ¼ 8) was significant (P ¼ 0.001; Kaplan-Meier OS analysis, log-rank test), but less than that made by expression profiles (P ¼ 0.05 versus P ¼ 0.003, Fisher's exact test). Moreover, the prognostic impact of our gene set persisted when applied to patients without metastasis at diagnosis as well as to patients without metastasis and lymph node invasion. No multivariate analysis was made because of the limited sample size of our series. Even if these results were obtained on a small series of tumours with relative over-representation of MSI cases, low stages and proximal colon cancer when compared with the common CRC population, they are encouraging and warrant further investigation. Validation studies with larger and more representative cohorts -now planned in our institution -are strongly required to extrapolate this promise to the common population.
The functional identities of the discriminator genes may provide insight into metastatic process and help identify potential therapeutic targets. Here also various cellular processes were represented. Among the known genes that were downregulated in metastatic tumours were DSC2, encoding desmocollin 2, a desmosomal and hemi-desmosomal adhesion molecule of the cadherin family, and HPN, coding for hepsin, a transmembrane serine protease the favourable prognostic role of which has been recently highlighted in prostate cancer (Dhanasekaran et al., 2001; Luo et al., 2001; Ernst et al., 2002) . Decorin is a small leucine-rich proteoglycan abundant in ECM that negatively controls growth of CRC cells (Santra et al., 1995) and angiogenesis (Grant et al., 2002) . Low levels of mRNA have been associated with a poor prognosis in breast carcinomas (Troup et al., 2003) . NME1 and NME2, tandemly linked potential metastasis-suppressor genes (Steeg, 2003) , were both downregulated. Prohibitin is a mitochondrial protein thought to be a negative regulator of cell proliferation and may be a TSG . Transcription of nuclear genes encoding mitochondrial proteins has been shown to be decreased during progression of CRC (Birkenkamp-Demtroder et al., 2002) . This was confirmed in our study since all discriminator genes involved in mitochondrial metabolism were downregulated in metastatic tumours (ATP5C1, BCKDK, CABC1, CKMT2, COX5B, COX6B, COX7A2, COX7-A2L, COX7C, HSPA9B, LRIG1, MDH1, NDUFA1, NDUFA4, NDUFA6, NDUFA9, NDUFV1, SCO1, UQCR). Surprisingly, although increased protein synthesis is classically associated with oncogenic transformation, we found many genes coding for ribosomal proteins (RPL5, RPL6, RPL15, RPL29, RPL31, RPL39) that were downregulated in metastatic tumours. To date, we have no explanation for this observation. The SMAD1/MADH1 gene, which codes for a transmitter of TGFb signalling, involved in metastatic process, was also downregulated.
The top upregulated gene in metastatic tumours was PCSK7, which codes for the proprotein convertase subtilisin/kexin type 7. Proprotein convertases (PCs) process latent precursor proteins into their biologically active products, including protein tyrosine phosphatases, growth factors and their receptors, and enzymes like matrix metalloproteases (MMPs), and thus may have a functional role in the tumour cell invasion and tumour progression. Other upregulated genes encoded various signalling proteins including PRAME, an interactor of the cytoskeleton-regulator paxillin, IQ-GAP1, a negative regulator of the E-cadherin/catenin complex-based cell-cell adhesion (Nabeshima et al., 2002) , LTPB4, a structural component of connective tissue microfibrils and local regulator of TGFb tissue deposition and signalling (Sterner-Kock et al., 2002) , and IGF1R1. IGF1R has been recently shown to be involved in metastases of CRC by preventing apoptosis, enhancing cell proliferation and inducing angiogenesis (Reinmuth et al., 2002) . Several genes located on the long arm of chromosome 15 were downregulated in metastatic samples (Korn et al., 1999) .
Expression profiles and lymph node metastasis
Nodal metastasis is the best, although imperfect, predictor of survival for CRC patients. However, approximately one-third of node-negative CRCs recur, possibly due to understaging and inadequate pathological examination of lymph nodes. Expression profiles DNA microarray and colon cancer F Bertucci et al defined on primary tumour could help predict the presence of lymph node metastasis as recently reported (Hippo et al., 2001; West et al., 2001; Huang et al., 2003) . We identified 46 genes and ESTs as discriminator between node-positive and node-negative tumours.
As expected, since lymph node status and metastatic relapse are inter-related events, our list included genes that we identified as discriminator between tumours with or without metastasis. For example, OAS1 and NTRK2 were overexpressed in node-positive tumours. NTRK2, encoding a neurotrophic tyrosine kinase, has been recently found to be mutated in CRC (Bardelli et al., 2003) and plays a role in metastastic process (Walch and Marchetti, 1999) . OAS1 encodes the 2 0 ,5 0 -oligoadenylate synthetase 1. High levels of activity of the 2-5A system have been reported in individuals with disseminated cancer (Merritt et al., 1985) , and a recent study found overexpression of OAS1 mRNA in nodepositive breast cancers (Huang et al., 2003) . Conversely, MGP, PRSS8 and NME2 were downregulated in nodepositive tumours. MGP encodes the matrix G1a protein, the loss of expression of which has been associated with lymph node metastasis in urogenital tumours (Levedakou et al., 1992) . The prostasin serine protease, encoded by PRSS8, is a potential invasion suppressor the downregulation of which may contribute to invasiveness and metastatic potential (Chen and Chai, 2002) .
Our list of 46 discriminator clones also included additional genes, reflecting the nonperfect correlation between lymph node metastasis and visceral metastasis and the involvement of different underlying biological processes. Among genes underexpressed in node-positive tumours were BUB3, TPP2 and ITIH1. BUB3 codes for a mitotic spindle checkpoint protein that interacts with the APC protein to regulate chromosome segregation during cell division. Defects in mitotic checkpoints, including mutations of BUB1, have been associated with CRC (Cahill et al., 1998) , and BUB genes (BUB1 and BUB1B) are underexpressed in highly metastatic colon cell lines (Hegde et al., 2001) . TPP2 encodes tripeptidyl peptidase II, a high molecular mass serine exopeptidase that may play a functional role by degrading peptides involved in invasive and metastatic potential as recently reported for DPP4 (Kajiyama et al., 2003) . ITIH1 encodes a heavy chain of proteins of the ITI family, which inhibits the metastatic spreading of H460 M large cell lung carcinoma lines by increasing cell attachment (Paris et al., 2002) .
Expression profiles and MSI phenotype
There are at least two distinct pathways of oncogenesis in sporadic CRC. A total of 15% of tumours present the MSI phenotype, which is related to the inactivation of MMR genes, principally MSH2 and MLH1 (reviewed in Peltomaki, 2003) . The genetically unstable tumour cells accumulate somatic clonal mutations in their genome, which may disturb mRNA expression or degradation of specific transcripts. Conversely, 85% of sporadic tumours are associated with a non-MSI (or MSS) phenotype; they are characterized by chromosome instability and loss of genomic material that may account for the loss of expression of specific alleles. Reliable distinction between MSI þ and non-MSI phenotypes, currently based on molecular approaches (Zhou et al., 1998) , remains problematic. Due to the number and large sequence length of the genes involved, the absence of mutation hot-spots, and the possibility of epigenetic inactivation, confirmation of MMR gene alteration is time consuming and difficult in routine clinical practice. Other methods are being tested such as IHC assessment of MSH2 and MLH1 (Perrin et al., 2001; Lindor et al., 2002; Wahlberg et al., 2002) . Furthermore, although the underlying molecular mechanisms of MSI þ and non-MSI colorectal oncogenesis remain unclear, it is thought that these two phenotypes represent different molecular entities that could translate into distinct gene expression profiles usable in clinical practice as new diagnostic markers and/or tests.
Our supervised analysis of MSI þ and non-MSI CRC clinical samples showed 58 differentially expressed clones. It is of note that arrayed MMR genes (MSH2, MSH3, MLH1, MLH3, PMS1 and PMS2) were not among these genes. As reported for cell lines (Dunican et al., 2002) , several of deregulated genes are involved in cell cycle control, mitosis, transcription and/or chromatin structure (RAN, PTPN21, TP53, MORF4L1, ZFP36L2, PSEN1, IGF2, ASNS, RPS4X, CCNF, ZNF354A). The top downregulated gene in MSI þ tumours was EIF3S2, which encodes the eukaryotic translation initiation factor 3, subunit 2b, also known as TRIP1. TRIP1 specifically associates with TGFBRII, a serine/threonine kinase receptor frequently inactivated by mutation and downregulated in MSI þ tumours (Markowitz et al., 1995) .
Validation studies
The concordance between our data and those from literature with respect to the identity of discriminator genes and their function strengthens the validity of our results. However, these genes do not point to an obvious mechanism of oncogenesis. For many genes, published data are scarce and our results may stimulate new investigations, notably through the identification of uncharacterized ESTs. Many different cell processes appear affected during colorectal oncogenesis. Variations of the expression of many genes involved in basic mechanisms (translation, metabolism) seem a mere consequence of the hyperactivity of cancer cells. Genes involved in adhesion processes are affected in metastasis but this could have been expected. Genes known to be affected in oncogenesis, such as MMR genes, do not discriminate tumour subgroups. More work is thus needed to sort out novel alterations that may intervene in the initiation or development of the disease.
In contrast, DNA microarray data could prove rapidly useful in clinical practice and design of new therapeutic strategies. Discriminator genes represent potential new diagnostic and prognostic markers and/ or therapeutic targets and deserve further investigation in larger series of patients. We have analysed protein expression of some differentially expressed molecules using IHC on TMA containing 191 pairs of cancer samples and corresponding normal mucosa. Such an approach is used to both validate the DNA microarray results and extend data using methods more widely available in routine clinical practice. However, it encountered several limitations: absence of available antibodies for many proteins, antibodies that did not perform well in IHC on paraffin-embedded tissues and absence of correlation between protein and mRNA levels. TMA results confirmed the correlations between NM23 expression level and two clinical parameters: noncancerous or cancer status and survival of patients. Expression was higher in cancer samples and low expression was significantly associated with a shorter survival. Such prognostic correlation has been described in a variety of tumours including breast (Niu et al., 2002) , ovarian (Tas et al., 2002) , lung (Katakura et al., 2002) or gastric (Kodera et al., 1994) cancers as well as melanoma (McDermott et al., 2000) . However, it remains controversial in CRC with positive (Indinnimeo et al., 1997; Berney et al., 1999; Dursun et al., 2002) and negative (Lindmark, 1996; Lee et al., 2001; Gunther et al., 2002) reports. In our analysis, which represents one of the largest series of CRC samples simultaneously tested for NM23 IHC and under highly standardized conditions using TMA, the adjusted odd ratios suggested a favourable impact of positive NM23 status on the clinical outcome, but such association lost significance in multivariate analysis. Larger series with several hundreds of patients are thus required to draw any definitive conclusion.
In conclusion, our study shows that mRNA expression profiling of CRC using DNA microarrays can identify clinically relevant tumour subgroups, defined upon combined expression of dozens or hundreds of genes. Validation studies on larger series of samples are now required to confirm these data, as well as studies investigating whether discriminator genes are, or are not, functionally relevant to oncogenesis and disease progression. By delineating these genes, understanding CRC development and progression will be improved and new diagnostic and/or prognostic markers, and new molecular targets for alternative anticancer drugs might soon be developed, leading to improvements in CRC management.
Materials and methods
Colorectal cancer patients and samples
A total of 50 samples (45 tissue samples and five cell lines) were profiled using DNA microarrays. The 45 colon tissue samples were obtained from 26 patients with sporadic colorectal adenocarcinoma who underwent surgery at the Institut Paoli-Calmettes (Marseille, France) between 1990 and 1998. Samples were macrodissected by pathologists, and frozen within 30 min of removal in liquid nitrogen for molecular analyses. All tumour samples contained more than 50% of tumour cells. These samples included 22 cancer samples and 23 normal samples divided into 19 tumour-normal pairs (availability of sample of the corresponding normal colonic mucosa), and three tumours and four normal specimens from seven different patients. All tumour sections and medical records were de novo reviewed prior to analysis. MSI phenotype of 22 cancers was determined by PCR amplification using BAT-25 and BAT-26 oligonucleotide primers and by IHC using anti-MSH2 and MLH1 antibodies (Perrin et al., 2001) . Tumours with alterations in both BAT markers were classified as MSI þ . No attempt was made to further classify tumours into MSI-high and MSI-low phenotype. The patients were selected to search for gene expression signatures associated with different characteristics (MSI phenotype, location of tumour, lymph node status and clinical outcome). Main characteristics of patients and tumours are listed in Table 1 . After colonic surgery, patients were treated (delivery of chemotherapy or not) according to standard guidelines . After completion of therapy, they were evaluated at 3-month intervals for the first 2 years and at 6-month intervals thereafter. Search for metastatic relapse included clinical examination and blood tests completed by yearly chest X-ray and liver ultrasound and/or CT scan.
Five samples were represented by two different sporadic colon cancer cell lines with chromosomal instability phenotype, Caco2 and HT29. Three samples represented Caco2 in a differentiated state (named Caco2A, 2B and 2C) -i.e. at confluence (C), at C þ 10 days, at C þ 21 days -and one sample represented Caco2 undifferentiated (named Caco2D). Cell lines were obtained from the American Type Culture Collection (http://www.atcc.org/) and grown as recommended.
For the IHC study on TMA, a consecutive series of 191 unselected sporadic CRC patients (including the 26 cases studied by DNA microarrays) treated between 1990 and 1998 at the Institut Paoli-Calmettes were selected. There were 99 men and 92 women. The median age of patients at diagnosis was 64 years (range 29-97). In 25% of the cases, tumours were located in the right colon, in 57% in the left colon, and in 11% in the rectum (Table 2) .
RNA extraction
Total RNA was extracted from frozen samples by using guanidinium isothiocyanate and caesium chloride gradient, as previously described (Theillet et al., 1993) . RNA integrity was controlled by denaturing formaldehyde agarose gel electrophoresis and 28S Northern blots.
DNA microarrays preparation
Gene expression analyses were carried out with home-made Nylon microarrays containing 8074 spotted cDNA clones, representing 7874 IMAGE human cDNA clones and 200 control clones. According to the 155 Unigene release, the IMAGE clones were divided into 6664 genes and 1210 ESTs. All clones were PCR-amplified in 96-well microtitre plates (200 ml). Amplification products were desiccated and resuspended in 50 ml of distilled water. They were then spotted as previously described (Bertucci et al., 1999b) onto Hybond-N þ 2 Â 7 cm 2 membranes (Amersham) stuck to glass slides using a 64-pin print head on a MicroGridII microarrayer (Apogent Discoveries, Cambridge, England). All membranes used in this study belonged to the same batch.
DNA microarray hybridizations
Microarrays were hybridized with 33 P-labelled probes, first with an oligonucleotide sequence common to all spotted PCR products (called vector hybridization to determine precisely the amount of target DNA accessible to hybridization in each DNA microarray and colon cancerspot), then after stripping, with complex probes made from 2 mg of retrotranscribed total RNA (Bertucci et al., 1999a, b) . Probe preparations, hybridizations and washes were carried out as described previously (http:/tagc.univ-mrs.fr/pub/Cancer/). After washes, arrays were exposed to phosphor-imaging plates that were then scanned with a FUJI BAS5000 machine (25 mm resolution). Hybridization signals were quantified using ArrayGauge software (Fuji Ltd, Tokyo, Japan).
Data analysis
Signal intensities were normalized for the amount of spotted DNA (Bertucci et al., 1999b) and the variability of experimental conditions (Bertucci et al., 1999a) . Briefly, complex probe intensity of each spot ('C') was first corrected ('C/V') for the amount of target DNA accessible to hybridization as measured using vector hybridization ('V'). When 'V' intensity of a spot was too weak on a microarray, the corresponding cDNA clone was not considered for this experiment (missing data). Then, to minimize experimental differences between different complex probe hybridizations, 'C/V' values from each hybridization were divided by the corresponding median value of 'C/V'.
Genes with expression levels present in at least 80% of the experiments and standard deviation greater than 0.5 were selected for the clustering analyses (3631 genes). Unsupervised hierarchical classification investigated relationships between samples and relationships between genes. It was applied to data log-transformed and median-centred on genes using the Cluster and TreeView program (average linkage clustering using Pearson's correlation as similarity metric) (Eisen et al., 1998) . We also used supervised analysis to identify and rank genes that distinguish between two subgroups of samples identified by histoclinical parameters. A discriminating score (DS) was calculated for each gene (Golub et al., 1999) as DS ¼ (M1ÀM2)/(S1 þ S2) where M1 and S1, respectively, represent mean and standard deviation of expression levels of the gene in subgroup 1, and M2 and S2 in subgroup 2. Confidence levels were estimated by bootstrap resampling as described previously (Magrangeas et al., 2003) . A 'leave-oneout' procedure (Golub et al., 1999) was applied to estimate the accuracy of prediction of our 'molecular metastatic signature' and the validity of our supervised analysis.
Statistical analyses were performed using the SPSS software (version 10.0.5). MFS and OS were measured from diagnosis until respectively the date of the first distant metastasis and the date of death from CRC. Follow-up was measured from the date of diagnosis to the date of last news for live patients. Survivals were estimated with the Kaplan-Meier method and compared between groups with the log-rank test. Data concerning patients without metastatic relapse or death at last follow-up were censored as well as deaths from other causes. A P-value o0.05 was considered significant.
Tissue microarrays construction
TMA were prepared as described (Richter et al., 2000) with slight modifications (Ginestier et al., 2002) . For each sample, three representative sample areas were carefully selected from a haematoxylin-eosin-stained section of a donor block. Core cylinders with a diameter of 0.6 mm each were punched from each of these areas and deposited into three separate recipient paraffin blocks using a specific arraying device (Beecher Instruments, Silver Spring, MD, USA). In addition to pairs of tumour and normal mucosa, the recipient block also received control tissues (small intestine, adenomas) and cell line pellets. In all, 5 mm sections of the resulting TMA block were made and used for IHC analysis after transfer onto glass slides. Two colon tumour cell lines (CaCo 2 , HT29) and one gastric tumour cell line (HGT1) were used as controls.
Immunohistochemical analysis
Anti-NM23 rabbit polyclonal antibody was purchased from Dako (Dako, Trappes, France) and used at 1 : 100 dilution. IHC was carried out on 5 mm sections of tissue fixed in alcohol formalin for 24 h and included in paraffin. Sections were deparaffinized in histolemon (Carlo Erba Reagenti, Rodano, Italy) and rehydrated in graded alcohol. Antigen enhancement was carried out by incubating the sections in target retrieval solution (Dako) as recommended. The reactions were carried out using an automatic stainer (Dako Autostainer). Staining was done at room temperature as follows: after washes in phosphate buffer, followed by quenching of endogenous peroxidase activity by treatment with 3% H 2 O 2 , slides were first incubated with blocking serum (Dako) for 30 min and then with the affinity-purified antibody for 1 h. After washes, slides were incubated with biotinylated antibody against rabbit immunoglobilin for 20 min followed by streptadivin-conjugated peroxydase (Dako LSAB R 2 kit). Diaminobenzidine was used as the chromogen. Slides were counterstained with haematoxylin, and coverslipped using Curemount (Instrumedics, Hackensack, USA) mounting solution. They were evaluated under a light microscope by two pathologists (GM, ECJ). The results were expressed in terms of percentage (P) and intensity (I) of positive cells as previously described (Hoos and Cordon-Cardo, 2001 ): results were scored by the quick score (Q) (Q ¼ P Â I). For the TMA, the mean of the score of two core biopsies minimum was calculated for each case. Correlations between status of sample (noncancerous or cancer and cancer with or without metastasis) or KaplanMeier MFS curves and IHC data were investigated by using Fisher's exact test and log-rank test in univariate analysis. The influence of significant measurement, adjusted for other factors, was assessed in multivariate analysis by the Cox proportional hazard models. Statistical tests were two-sided at the 5% level of significance.
